insights_auto
Waarom is EVGN gedaald 4,09%?
Meer informatiechevron_right
EVGN:NASDAQ
Evogene Ltd
US$Â 0,38
arrow_downward
-4,09%(-0,016) 1D
9 okt, 16:00:00 GMT-4 · USD
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor EVGN genereren…
Openen
US$Â 0,39
Hoog
US$Â 0,39
Laag
US$Â 0,37
Beursw.
6,87Â mln.
Gem. vol.
2,57Â mln.
Volume
106,04K
52 wk hoog
US$Â 1,49
52 wk laag
US$Â 0,35
WPA
US$Â -0,90
Bèta
1,44
Uitstaande aandelen
18,05Â mln.
Aantal medewerkers
52
Openen
US$Â 0,39
Hoog
US$Â 0,39
Laag
US$Â 0,37
Beursw.
6,87Â mln.
Gem. vol.
2,57Â mln.
Volume
106,04K
52 wk hoog
US$Â 1,49
52 wk laag
US$Â 0,35
WPA
US$Â -0,90
Bèta
1,44
Uitstaande aandelen
18,05Â mln.
Aantal medewerkers
52
Nieuwsartikelen
Van webbronnen en nieuwspartners
Stock Titan
·
3 dagen geleden
Holders of about 16.93% sign an Evogene (EVGN) deal that would reshape its board if approved.
Investing.com South Africa
·
3 dagen geleden
Evogene reaches agreement with Pure Capital Group on board changes By Investing.com
Profiel
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
Over Evogene Ltd